IL97055A0 - Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives - Google Patents

Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives

Info

Publication number
IL97055A0
IL97055A0 IL97055A IL9705591A IL97055A0 IL 97055 A0 IL97055 A0 IL 97055A0 IL 97055 A IL97055 A IL 97055A IL 9705591 A IL9705591 A IL 9705591A IL 97055 A0 IL97055 A0 IL 97055A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
tumor cells
sensitizing tumor
quinazolinedione derivatives
quinazolinedione
Prior art date
Application number
IL97055A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL97055A0 publication Critical patent/IL97055A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL97055A 1990-02-13 1991-01-25 Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives IL97055A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47932090A 1990-02-13 1990-02-13
US07/497,049 US5160727A (en) 1990-02-13 1990-03-21 Tumor cell sensitization method using quinazolinedione derivatives

Publications (1)

Publication Number Publication Date
IL97055A0 true IL97055A0 (en) 1992-03-29

Family

ID=27046201

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97055A IL97055A0 (en) 1990-02-13 1991-01-25 Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives

Country Status (11)

Country Link
US (1) US5160727A (de)
EP (1) EP0524931B1 (de)
JP (1) JPH05509290A (de)
KR (1) KR927003058A (de)
AT (1) ATE121622T1 (de)
AU (1) AU646837B2 (de)
CA (1) CA2076032A1 (de)
DE (1) DE69109283T2 (de)
IE (1) IE910476A1 (de)
IL (1) IL97055A0 (de)
WO (1) WO1991012006A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
US5491234A (en) * 1992-03-30 1996-02-13 Pfizer Inc. Pyrimidine derivatives for enhancing antitumor activity
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
DE19512484A1 (de) * 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
CA2546002C (en) 2003-11-20 2012-09-18 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
BRPI0416206A (pt) 2003-11-20 2006-12-26 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose)
EA011552B1 (ru) 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
SG154433A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Phthalazine derivatives as parp inhibitors
ATE540936T1 (de) 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
KR101188688B1 (ko) 2004-06-30 2012-10-09 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 퀴나졸린디온 유도체
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
CN101981013B (zh) 2008-03-27 2013-05-29 詹森药业有限公司 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
ES2367760T3 (es) 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819630A (en) * 1972-08-21 1974-06-25 R Parcell 3-(1-piperazinylalkyl)-2,4-quinazolinedione compounds and methods for their production
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
JPS608274A (ja) * 1983-06-27 1985-01-17 Fujisawa Pharmaceut Co Ltd 新規キナゾリノン誘導体およびその製造法・並びに抗アレルギ−剤
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents

Also Published As

Publication number Publication date
IE910476A1 (en) 1991-08-14
WO1991012006A2 (en) 1991-08-22
EP0524931B1 (de) 1995-04-26
DE69109283T2 (de) 1995-08-24
JPH05509290A (ja) 1993-12-22
KR927003058A (ko) 1992-12-17
US5160727A (en) 1992-11-03
AU646837B2 (en) 1994-03-10
ATE121622T1 (de) 1995-05-15
EP0524931A1 (de) 1993-02-03
CA2076032A1 (en) 1991-08-14
DE69109283D1 (de) 1995-06-01
AU7154491A (en) 1991-09-03

Similar Documents

Publication Publication Date Title
IL97055A0 (en) Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives
NO970039D0 (no) Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
RU93051543A (ru) Производные акридина, способ получения, фармацевтическая композиция и способ лечения злокачественных опухолей
CY1108363T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν τριοξειδιο αρσενικου για την θεραπεια του μη-hodgkin λεμφωματος
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
ZA921911B (en) 2,4-diaminoquinazoline derivatives for enhancing anti-tumor activity.
IL118426A (en) Pharmaceutical composition containing 1,3- bis-triazolyl-2-propanol derivative for treating cancer tumors or viruses
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
FI960658L (fi) Uudet bis-naftalimidit syövän hoitamiseksi
HUT68876A (en) Pharmaceutical composition for treating tumours, containing creatine phosphate or phospho-enol-pyruvic acid
DE69225043D1 (de) Injizierbares Pulver zur Behandlung von Krebs
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
AU6182994A (en) Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy
DK0588873T3 (da) Behandling af levercancer
TR200102576T2 (tr) Kanser tedavisinde radyoaktif sisplatin
RU97111568A (ru) Способ лечения онкологических больных
EP0938900A4 (de) Mittel zur vorbeugung bzw. heilung der stomatitis
IL106763A0 (en) Pharmaceutical compositions for treating cancer
SE8103404L (sv) Tennforeningar, sett att framstella dem, sett att framstella ett lekemedelspreparat under anvendning av en dylik tennforening for behandling av cancer samt det pa sa sett erhallna lekemedelspreparatet
CA2103708A1 (en) Treatment of ovarian cancer
EP0793499A4 (de) Verfahren und mittel zur verminderung der tumorentwicklung mittels einer kombination aus einer taxanverbindung und einer tellur und/oder selenverbindung
EP0870510A3 (de) Synergistische Zusammensetzung enthaltend Cryptophycinderivate und synergistische mikrotubuli Mitteln